Selank is a synthetic peptide developed in Russia by the Institute of Molecular Genetics. It was derived from tuftsin, a naturally occurring peptide your immune system produces that also has effects in the brain. Researchers modified tuftsin to create a compound that crosses the blood-brain barrier more reliably and acts specifically on anxiety and cognitive function. It's been approved in Russia as an anxiolytic and nootropic since the 1990s.
What sets Selank apart from conventional anxiety medications is how it works. Benzodiazepines (like Xanax or Valium) flood GABA receptors to forcibly suppress nervous system activity — they work fast but cause sedation, dependency, and withdrawal. Selank modulates anxiety through a different pathway involving serotonin, dopamine, and BDNF (brain-derived neurotrophic factor), producing calm without sedation, without dulling cognition, and without the dependency profile of benzos.
The cognitive enhancement effects are a significant part of its appeal. Users consistently report improved focus, clearer thinking, and better memory recall alongside the anxiety reduction. This profile — less anxious and sharper at the same time — is unusual. Most anxiety treatments cause some cognitive blunting as a side effect. Selank appears to do the opposite.
Research in Russia is extensive, though much of it hasn't been translated or published in Western journals. Human trials have shown significant reduction in anxiety symptoms with good tolerability and no withdrawal effects on discontinuation. It's typically administered as nasal drops, which allows direct absorption into the brain and avoids the short half-life that makes injection inconvenient.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. The lead researcher, Nikolai Myasoedov, and his team were looking for a safer alternative to benzodiazepines that could treat anxiety without the associated dependency and cognitive side effects.
Russian clinical studies have shown Selank to be effective for generalized anxiety disorder, with improvements comparable to traditional anxiolytics but without the sedation or tolerance development. It's been approved in Russia as a pharmaceutical drug for anxiety and cognitive disorders.
The BDNF-increasing effect is scientifically interesting independent of the anxiety application. BDNF is critical for neuroplasticity — the brain's ability to form new connections and adapt. Low BDNF is associated with depression, cognitive decline, and poor stress response. Compounds that reliably increase BDNF are of significant interest to neurologists and longevity researchers.
Western research on Selank is growing but still limited compared to the Russian literature. Animal studies have confirmed its anxiolytic and nootropic effects and established it as well-tolerated. The nasal delivery format makes it practical and fast-acting compared to most peptides that require injection.
No reviews yet. Be the first.